|
Video: What is a Stock Split?
|
|
Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Co.'s U.S. Food and Drug Administration approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, an oral spleen tyrosine kinase inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe, the U.K. (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. According to our Rigel Pharmaceuticals stock split history records, Rigel Pharmaceuticals has had 0 splits. | |
|
Rigel Pharmaceuticals (RIGL) has 0 splits in our Rigel Pharmaceuticals stock split history database.
Looking at the Rigel Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Rigel Pharmaceuticals shares, starting with a $10,000 purchase of RIGL, presented on a split-history-adjusted basis factoring in the complete Rigel Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/07/2014 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$2.75 |
|
End price/share: |
$1.20 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-56.36% |
|
Average Annual Total Return: |
-7.96% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,363.80 |
|
Years: |
10.00 |
|
|
|
|
|